Cancer Commons, in partnership with the Musella Foundation For Brain Tumor Research & Information, conducted a pilot study seeking to improve outcomes for current glioblastoma (GBM) patients and identify promising therapies for development. The study used genomic sequencing and other biomarker testing to recommend individualized treatment regimens and captures and analyzes clinical outcomes to inform treatment for future patients.
While the study is not currently enrolling new patients, Cancer Commons welcomes GBM patients and their caregivers to register with Cancer Commons to receive our services. Our one-on-one support is driven by the latest, evidence-based scientific discoveries.
For help with the consent and registration process or if you have questions, please or call our Patient Helpline at 877-971-1200 or contact firstname.lastname@example.org.